Table 3.
Hazard ratios (95% CI) of death from total cancer and cancer types by quartiles of serum B2M; ARIC, 1990–2011.
| Cause of death | No. of deaths |
Quartiles of B2M (mg/L) | ||||
|---|---|---|---|---|---|---|
| ≤1.66 | 1.67–1.88 | 1.89–2.15 | ≥2.16 | P-trend | ||
| Total cancer | 1160 | 237 | 261 | 322 | 344 | |
| Person-years | 219,393 | 57,374 | 57,868 | 54,563 | 49,588 | |
| Mortality ratea | 5.29 | 4.13 | 4.51 | 5.90 | 6.94 | |
| Model 2b | 1 (reference) | 0.92 (0.76–1.12) | 1.09 (0.89–1.34) | 1.30 (1.02–1.64) | 0.01 | |
| Colorectal cancer | 85 | 13 | 27 | 24 | 21 | |
| Person-years | 219,393 | 57,374 | 57,868 | 54,563 | 49,588 | |
| Mortality rate | 0.39 | 0.23 | 0.47 | 0.44 | 0.42 | |
| Model 2 | 1 (reference) | 1.60 (0.77–3.32) | 1.50 (0.68–3.33) | 1.73 (0.68–4.44) | 0.34 | |
| Lung cancer | 352 | 70 | 84 | 84 | 114 | |
| Person-years | 219,393 | 57,374 | 57,868 | 54,563 | 49,588 | |
| Mortality rate | 1.60 | 1.22 | 1.45 | 1.54 | 2.30 | |
| Model 2 | 1 (reference) | 1.05 (0.73–1.50) | 1.05 (0.72–1.55) | 1.69 (1.10–2.59) | 0.02 | |
| Breast cancer (women only) | 77 | 19 | 18 | 23 | 17 | |
| Person-years | 124,783 | 34,480 | 31,434 | 29,888 | 28,982 | |
| Mortality rate | 0.62 | 0.55 | 0.57 | 0.77 | 0.59 | |
| Model 2 | 1 (reference) | 1.12 (0.49–2.53) | 1.23 (0.51–2.95) | 0.80 (0.26–2.47) | 0.83 | |
| Prostate cancer | 58 | 14 | 15 | 20 | 9 | |
| Person-years | 94,609 | 22,894 | 26,434 | 24,676 | 20,605 | |
| Mortality rate | 0.61 | 0.61 | 0.57 | 0.81 | 0.44 | |
| Model 2 | 1 (reference) | 0.78 (0.36–1.68) | 0.93 (0.42–1.68) | 0.42 (0.14–2.07) | 0.25 | |
| Hematological cancers | 138 | 21 | 29 | 34 | 54 | |
| Person-years | 219,393 | 57,374 | 57,868 | 54,563 | 49,588 | |
| Mortality rate | 0.63 | 0.37 | 0.50 | 0.82 | 1.09 | |
| Model 2 | 1 (reference) | 1.21 (0.64–2.28) | 1.48 (0.78–2.82) | 2.44 (1.20–4.95) | 0.001 | |
Per 1,000 person-years
Multivariable model (Model 2, Table 2) – adjusted for age, sex, race, study center, education, BMI, smoking status and pack-years of smoking, use of aspirin, hormone replacement therapy (in women) and eGFR.